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Summary 
I.ntegrin/hgand binding evokes tyrosine phosphorylation of various proteins. We reported pre- 
viously that a 105 kD protein (ppl05)  was tyrosine phosphorylated by the engagement of [31 
integrins in T lymphocytes. We show here that ppl05 is a novel p130Cas (Crk-associated sub- 
strate)-related protein. Deduced amino acid sequence revealed that ppl05  contains conserved 
motifs with p130Cas, and both ppl05 and p130Cas bind to focal adhesion kinase (pp125FAK) 
and Crk. However, ppl05 has a clearly distinct structure from p130Cas, and ppl05 is preferen- 
tially expressed in lymphocytes, whereas p130Cas  is expressed in adherent cells. With these 
findings, we designate ppl05  as Cas-L, lymphocyte-type Cas.  Furthermore, we demonstrate 
that integrin/hgand binding results  in the recruitment of Crk, Nck, and SHPTP2 to ppl05. 
These findings further define the roles  of ppl05/Cas-L and pp125FAK in the integrin-medi- 
ated signaling pathways. 
T 
he [31  integrins play an important role in the interac- 
tion between T  cells and the surrounding extracellular 
matrix (1) and may aid lymphocyte migration into tissues (2). 
In addition to their role in cell adhesion, recent studies have 
clearly shown that integrins transduce signals into the inte- 
rior of T  lymphocytes and other types of cells (3). We and 
others have shown that the binding of T  cells to the extra- 
cellular matrix through [31 integrins provides costimulatory 
signals for T cell proliferation  (4-9). We also identified protein 
tyrosine phosphorylation as a [31 integrin-mediated biochemi- 
cal signal occurring before T  cell proliferation. The engage- 
ment of [31 integrin molecules induced tyrosine phosphoryla- 
tion of 140-,  120-,  110-105-,  80-70-, 60-55-, and 45-kD 
proteins in peripheral T cells (10-12).  Several tyrosine-phos- 
phorylated proteins have been identified, such as phospholi- 
pase C  (PLC)-~/ (pp140), focal adhesion kinase  (pp125FAK 
[pp120]) l, paxillin (pp70),  p59Fyn/p56Lck (pp60-55),  and 
mitogen-activated protein (MAP) kinase (pp45) (10). How- 
1Abbreviations used in  this paper: Cas, Crk-associated substrate; CT, 
COOH-terminal domain; FAK, focal adhesion kinase; FN, fibronectin; 
GST, glutathione-S-transferase;  PLL, poly-t-lysine;  SH, Src homology; 
SOS, son ofsevenless. 
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ever, a 105-kD tyrosine-phosphorylated protein (ppl05) has 
not been identified. 
ppl05  is a protein that we first identified in T  lympho- 
blastoid H9 cells as well as peripheral T  cells (11). ppl05 is 
a  105-kD  protein  that is  tyrosine phosphorylated by the 
engagement of 0L4131 integrin. Our previous studies dem- 
onstrated that ppl05  is distinct from pp125FAK, although 
both ppl05 and pp125FAK are tyrosine phosphorylated via 
similar kinetics by the engagement of oL4[~l integrin in H9 
ceils  (12). Given the fact that ppl05  is one of the major 
proteins  that  is  tyrosine  phosphorylated  by  [31  integrin 
stimulation in peripheral T cells, ppl05 may play an impor- 
tant role in [31 integfin-mediated signaling in T  cells. 
Recently, Sakai et al. (13) cloned the cDNA ofpl30Cas 
(Crk-associated substrate),  p130Cas  was  originally identi- 
fied as  a  tyrosine-phosphorylated 130  kD  protein  in  the 
p60  v-src- or p47V-Crk-transformed fibroblasts.  The deduced 
amino  acid  sequence  of pl30Cas  revealed  that  p130Cas 
contained one Src homology (SH)  3 domain in the NH  z- 
terminal region and multiple putative binding sites of SH2 
domains. Tyrosine phosphorylated pl30Cas bound to Crk, 
and the  deduced amino  acid sequence  of p130Cas  con- 
tained multiple binding motifs of the  Crk  SH2  domain. 
Crk can bind to guanine nucleotide-releasing factors son of 
sevenless  (SOS)  and C3G by the SH3 domain of Crk (14, 
15). SOS  and C3G are  involved in the activation of Kas 
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that  tyrosine-phosphorylated p130Cas  is  involved  in  the 
activation  of Ras  family proteins  by  the  association with 
Crk.  Moreover, we demonstrated that p130Cas is tyrosine 
phosphorylated  by  [31  integrin  stimulation  in  fibroblasts 
(18).  On  the  other  hand,  Poke  and  Hanks  (19)  reported 
that p130Cas bound to pp125FAK via its SH3 domain. 
In this study, we demonstrate that pp 105 is a novel Cas- 
related protein  that  is  expressed in  lymphocytes.  We  also 
show the predicted structure ofppl05  based on an isolated 
cDNA.  Furthermore,  we  show  that  ppl05  binds  to  FAK 
and other signaling molecules, including Crk.  These find- 
ings further suggest the  role of ppl05  in  the  [31  integrin- 
mediated signaling pathways. 
Materials  and Methods 
Cell Culture.  Rat 3Y1, SR-3Y1, T-47D, HL-60, K-562, U937, 
H9,  HPB-ALL, Jurkat, 1Zaji, and Cos-1  cell lines were obtained 
from American Type  Culture  Collection (Rockville, MD)  and 
grown in DMEM or R.PMI 1640 medium supplemented with heat- 
inactivated FCS,  2  mM  L-glutamine, and  gentamycin  (50  ~g/ 
ml). Peripheral T  cells and B cells were isolated from healthy do- 
nors as described previously (10).  Fresh normal thymocytes were 
obtained from thymuses removed from patients at corrective car- 
diac surgery. A portion of thymus was  finely minced, and a sin- 
gle-cell  suspension  was  prepared  by  pressing  the  fragments 
through a stainless steel mesh. RBCs and debris were removed by 
centrifugation over Ficoll-Paque (Pharmacia LKB, Uppsala, Swe- 
den), and then thymocytes were washed three times. 
GST Fusion Proteins.  Plasmids coding glutathione-S-transfer- 
ase  (GST)  fusion proteins were  constructed by the insertion of 
human  FAK cDNA  fragments  into  pGEX-3X  or  pGEX-2TK 
(Pharnaacia  LKB). GST-COOH-terminal domain (CT) contains 
FAK amino acid residues from 706  to  1,052,  GST-AH contains 
amino acid residues from 706 to 904, and GST-H1 contains resi- 
dues from 896 to  1,052  (20).  GST-AblSH2 was provided by Dr. 
Wayne  G.  Haser  (Dana-Farber Cancer  Institute,  Boston,  MA) 
(21).  GST-CrkSH2  and  GST-NckSH2  were  provided by  Dr. 
Bruce J.  Mayer (Children's Hospital, Boston,  MA)  (22).  GST- 
LckSH2 and GST-ShcSH2 were provided by Dr. Gotz Baumann 
(Sandoz Pharma LTD., Basel, Switzerland)  (23). GST-SHPTP2SH2 
was  obtained from Dr. Benjamin G. Neel (Beth  Israel  Hospital, 
Boston, MA)  (21).  GST-PI3KSH2 was obtained from Dr. Brian 
Schaffhausen  (Tufts University School of Medicine, Boston,/VIA) 
(21).  GST-Grb2SH2 was  constructed from human  Grb2 cDNA, 
which  was  obtained from  Dr.  Takeshi Urano  (Tufts  University 
School of Medicine, Boston,  MA). GST-CskSH2 was  generated 
from Csk cDNA, which was obtained from Dr. Masato Okada (In- 
stitute for Protein Research, Osaka University, Osaka, Japan).  GST- 
PLCySH2 was generated by reverse transcription PCP-. 
ImmunoblottingandImmunopredpitations.  H9  cells  were  washed 
three times, resuspended in Iscove's serum-free media, incubated 
in plates coated with poly-L-lysine (PLL;  Sigma Chemical Co., 
St.  Louis, MO) or human plasma fibronectin (FN; GIBCO BRL, 
Gaithersburg, MD), and then solubilized in a modified NP-40 ly- 
sis buffer (1% NP-40, 0.5%  deoxychofic acid,  150  mM  NaC1,  50 
nflVl Tris-HC1, 5 mM EDTA,  1 mM PMSF, 10 mM iodoaceta- 
mide, 1 txg/ml pepstatin A, 10 mM sodium fluoride, 10 mM so- 
dium pyrophosphate, and 0.4 mM sodium vanadate, pH 8.0)  or 
1% digitonin lysis buffer, which  contained  1% digitonin (Wako 
Pure  Chemical Industries Ltd.,  Osaka, Japan)  instead of NP-40 
and deoxycholic acid. 
For immunoprecipitation,  cell  extracts  were  incubated  with 
primary antibodies for 1 h at 4~  followed by additional incuba- 
tion with goat anti-mouse IgG-conjugated agarose (Sigma Chemi- 
cal  Co.)  or  rabbit  anti-mouse  lgG  (Jackson  ImmunoResearch 
Laboratories, Inc.,  West Grove,  PA)  plus protein  A-Sepharose 
(Pharmacia LKB)  for 1 h at 4~  Specific mAbs against Cas, Crk, 
pp125FAK,  Nck,  paxillin, and  SHPTP2  were  purchased  from 
Transduction Laboratories (Lexington, KY).  Otherwise, cell ex- 
tracts  were  incubated  with  glutathione  Sepharose  (Pharmacia 
LKB), which was conjugated with GST-fusion proteins for 1 h at 
4~  Beads were  washed  with  1%  NP-40  washing buffer  (1% 
NP-40,  50 mM Tris-HCl,  140 mM NaC1,  2.5 mM EDTA) five 
times. For sequential immunoprecipitations, washed beads were 
boiled 5 rain at 100~  in the presence of 2% SDS, and the super- 
natants were reprecipitated with antibodies in the 1% NP-40 lysis 
buffer containing 0.1%  final SDS  concentration.  For immuno- 
blotting, samples were fractionated by 7% SDS-PAGE under re- 
ducing  conditions  and  electro-transferred  onto  nitrocellulose 
membranes. Membranes were analyzed by immunoblotting with 
a chemiluminescence reagent (DuPont NEN, Boston, MA) after 
incubation with  primary Ab and horseradish peroxidase-conju- 
gated anti-mouse lgG (Amersham Corp., Arlington Heights, IL). 
Otherwise, membranes were incubated with T2q-labeled antiphos- 
phowrosine mAb (4G10; Upstate Biotechnology, Inc., Lake Placid, 
NY) (10). 
Overlay Assay.  For the overlay assay, pGEX-2TK fusion pro- 
tein  containing FAK residues 707-1,052  (GST-CT)  was  phos- 
phorylated  in  vitro  using  bovine  heart  muscle  kinase  (Sigma 
Chemical Co.)  and  [2/32p]ATP (DuPont  NEN).  Proteins trans- 
ferred to the membrane were denatured in 6 M  guamdine-HC1 
and subsequently renatured (24).  This membrane was hybridized 
with 32p-labeled GST-FAK fusion protein in buffer containing 
20 mM Hepes, pH 7.7,  75 mM KCI, 0.1  mM EDTA,  2.5  mM 
MgCI2,  1% nonfat dry milk, and 0.05% NP-40. 
Molecular Bielogy.  A  kgt11  cDNA  library constructed  from 
human lymphoma Hut78  RNA (CLONTECH,  Palo Alto, CA) 
was screened by anti-Cas mAb (Transduction Laboratory) and al- 
kaline phosphatase-conjugated goat anti-mouse IgG (Sigma Chem- 
ical Co.)  (25).  DNA sequencing was  performed by the dideoxy 
nucleotide  method  (25,  26).  Isolated cDNA  was  inserted  into 
pcDL-S1La for the transfection study in Cos-I  cells (27). pcDL- 
SRa-LckY505F  was  generated  from  DNA  provided  by  Dr. 
Roger M.  Perlmutter (University of Washington, Seattle, WA). 
pMT3-SrcY527F was provided by Dr.  Takeshi Urano.  pMT3- 
EE-CrkI and II were constructed from chicken Crk genes, which 
were provided by Dr. Bruce J. Mayer. Cos-I  cells were used for 
the  transfection study by the  DEAE-dextran method  (25).  For 
Northern  blotting, a  DNA fragment  of isolated cDNA  (nucle- 
otides 1,446-1,773) was 32p labeled and used as a probe (26). 
Results 
Association  of ppl05  with  the  COOH-terminal  Domain  of 
YAK.  In our previous Study, we demonstrated that ppl05 
and pp125FAK were  tyrosine phosphorylated by [31  inte- 
grin  stimulation  via similar kinetics  in  H9  cells,  although 
ppl05 is a distinct molecule from pp125FAK (12). Because 
pp125FAK is an  essential tyrosine kinase for  [31  integrin- 
mediated protein  tyrosine phosphorylation,  we  attempted 
to  define the  relationship between  pp125FAK and ppl05. 
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PLL-coated plates before cell lysis. H9 cell lysates were pre- 
cipitated with GST fusion protein of the pp125FAK COOH- 
terminal domain and analyzed by immunoblotting with an- 
tiphosphotyrosine mAb (anti-pTyr). As shown in Fig.  1 A, 
a tyrosine phosphorylated  105-kD protein precipitated on 
the  beads  conjugated  with  GST-CT  from FN-stimulated 
cell lysate (lane  6), whereas this protein did not precipitate 
on GST-conjugated beads (lane  4). This tyrosine phosphor- 
ylated protein  migrated at  the  same position  as ppl05  in 
FN-incubated  cell  lysate  (lane  2)  and  was  detected  only 
minimally in PLL-incubated cell lysate (lane  5). These results 
strongly suggest that ppl05 binds to the CT of pp125FAK. 
Paxillin  was also precipitated from H9  cell lysate and was 
detected by anti-pTyr as a  70-kD band  (lane  6),  as we  re- 
ported in  HPB-ALL and  T-47D  cells  (20).  To determine 
whether  ppl05  binds  to  FAK  or  paxillin,  H9  cell lysates 
were  precipitated  with  deletion  mutants  of GST-CT.  As 
shown in Fig. 1 B, ppl05 was precipitated with GST-AH, but 
not  with  GST-H1.  Conversely,  Paxillin  was  precipitated 
with  GST-H1 but not with GST-AH. These results dem- 
onstrate  that  ppl05  binds  to  the  FAK sequence  that  con- 
tains  amino  acid  residues  706-904.  This  ppl05-binding 
domain  of FAK is  distinct  from  the  paxillin-binding  do- 
main  of FAK,  indicating  that  ppl05/FAK  binding  is  not 
mediated via paxillin. 
Identification of  ppl05 as a Cas-related Protein.  ppl05 was 
precipitated with the  GST-FAK fusion protein from FN- 
stimulated  H9  cell  lysates  and  was  detected  by immuno- 
blotting  with  anti-pTyr.  A  130-kD  tyrosine-phosphory- 
lated  protein  was precipitated  with  the  GST-FAK fusion 
protein from human breast cancer-derived T-47D  cell ly- 
sates  (Tachibana,  K.,  and  T.  Sato,  unpublished  data).  We 
identified  this  130-kD  protein  as p130Cas  using anti-Cas 
mAb  (Transduction  Laboratories)  (Tachibana,  K.,  and  T. 
Sato,  unpublished  data).  Recently,  Polte  and  Hanks  (19) 
reported that p130Cas bound to FAK by its SH3 domain. 
FAK  residues  706-904,  which  were  sufficient  for  ppl05 
binding,  contained the reported p130Cas-binding site.  We 
attempted to determine ifppl05 was reactive with anti-Cas 
mAb. As shown in Fig.  2 A, a 105-kD protein was precipi- 
tated  with  the  GST-FAK fusion  protein  and  detected  by 
immunoblotting with  anti-Cas  mAb  (Transduction  Labo- 
ratory) (anti-Cas blot, lanes 3 and 4). This 105-kD protein 
showed the same migration in SDS-PAGE as ppl05, which 
was precipitated by the  GST-FAK fusion protein and de- 
tected by reblotting with anti-pTyr. We further performed 
a  second  immunoprecipitation  with  anti-Cas  mAb  after 
precipitation with the GST-FAK fusion protein. As shown 
in Fig.  2 A, a  105-kD Cas protein was precipitated first by 
the GST-FAK fusion protein and reprecipitated by anti-Cas 
mAb (anti-Cas blot). This 105-kD protein showed increased 
tyrosine phosphorylation by FN stimulation (Fig. 2 A, anti- 
pTyr blot,  lanes  5  and  6).  To  confirm that  ppl05  is  the 
molecule recognized by anti-Cas mAb, H9 cell lysates were 
immunoprecipitated with  anti-Cas mAb or anti-pTyr and 
analyzed  by immunoblotting.  As  shown  in  Fig.  2  B,  the 
105-kD  protein  that  was precipitated  with  anti-Cas  mAb 
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Figure  1.  Binding ofppl05 to the CT domain ofFAK. (A) H9 cells 
were incubated in PLL- or FN-coated plates for 30 rain (lanes 1, 3, and 5 
and 2, 4, and 6, respectively).  After lysis, cellular  lysates  were precipitated 
by glutathione beads that were conjugated to GST or GST-FAK CT fu- 
sion protein (containing FAK residues 706-1,052, GST-CT beads). The 
whole lysate and the immunoprecipitates  were analyzed  by immunoblot- 
ting with antiphosphotyrosine mAb (anti-pTyr). (B) H9 cell lysates  were 
precipitated with GST-FAK fusion protein~conjugated beads. GST-AH 
contains FAK residues 706-904, and  GST-H1 contains FAK residues 
896-1,052. Precipitates  were analyzed  by immunoblotting  with anti-pTyr. 
was  tyrosine  phosphorylated  by  the  stimulation  of  FN 
(anti-pTyr blot, lane  2).  Moreover,  a tyrosine phosphory- 
lated  105-kD  protein  that  was  precipitated  by  anti-pTyr 
was detected by anti-Cas mAb (anti-Cas blot, lane  6).  To 
determine  if this  105-kD  protein  recognized  by anti-Cas 
mAb is the  major tyrosine-phosphorylated protein among 
105-110-kD  proteins that are phosphorylated by the liga- 
tion of [31 integrins, we performed immunodepletion anal- 
ysis using anti-Cas mAb. As shown in Fig.  2  C, a clear dif- 
ference in the amount of tyrosine-phosphorylated 105-kD 
protein  was  observed  with  or  without  immunodepletion 
with hnti-Cas mAb in the whole lysates (lanes 2 and 4) and 
in the anti-pTyr precipitates (lanes  6 and 8). These findings 
indicate that ppl05, a 105-kD protein that is tyrosine phos- 
phorylated by [31 integrin stimulation, is a Cas-related protein. 
Differential  Expression  of  130-  and  105-kD  Cas  Proteins. 
p130Cas has been reported to migrate as discrete species of 
115  and  125  kD in SDS-PAGE  (designated by Sakai et al. 
[13] as Cas-A and Cas-B, respectively) in rat fibroblast 3Y1 
cells (also shown in Fig.  3).  However, a decrease in the size 
of Cas-A and the simultaneous appearance of a broad 130-kD 
Cas band (designated Cas-C) were observed in both v-Src- 
and v-Crk-transformed 3Y1  cells.  Because phosphorylated 
tyrosine  residues  were  found  predominantly  in  Cas-C, 
Cas-C appeared to be a modified form of Cas-A or Cas-B as 
the result oftyrosine phosphorylation (13). 
We identified ppl05 in H9 cells as a putative Cas-related 
protein,  ppl05  was originally identified  as a  105-kD  pro- Figure 2.  Identification ofppl05 as a Cas-related protein.  (A) H9 cell 
lysates were  prepared  from  cells that  were  incubated  on PLL- or FN- 
coated plates (lanes 1, 3, and 5 and 2, 4, and 6, respectively) for 30 rain. 
Cellular  lysates were  precipitated  with GST beads  (lanes 1 and 2)  or 
GST-CT beads (lanes 3-6). After precipitation, associated molecules were 
solubilized and reprecipitated with anti-Cas mAb (lanes 5 and 6). Precipi- 
tates were analyzed by imnmnoblotting  with anti-Cas mAb and rehybrid- 
ized with anti-pTyr.  (B) H9 cell lysates were immunoprecipitated  with 
anti-Cas mAb (lanes I and 2), without first Ab (lanes 3 and 4), or anti- 
pTyr mAb (lanes 5 and 6) and rabbit anti-mouse IgG (H+L) plus protein 
A-Sepharose. Whole lysates (lanes 7 and 8) and precipitates were analyzed 
by immunoblotting  with anti-Cas mAb (left) and then rehybridized with 
anti-pTyr (right). (C) H9 cell lysates were immunodepleted  with anti-Cas 
mAb (lanes 3, 4,  7, and 8) or without first Ab (lanes I, 2, 5, and 6). The 
immunodepleted lysates were kept as whole lysates (lanes 1-4)  or imnm- 
noprecipitated  with anti-pTyr Ab (lanes 5-8).  Lysates and immunopre- 
cipitates were analyzed by immunoblotting  with anti-pTyr. 
tein that was tyrosine phosphorylated by the stimulation of 
[31  integrins.  By  immunoblotting with  anti-pTyr,  ppl05 
was  detected  predominantly in  H9  cells  as  well  as  in pe- 
ripheral T  cells (11),  whereas ppl05  was not detected well 
in the  other T  cell lines. To determine the  distribution of 
ppl05  and p130Cas,  we  examined the  expression  and the 
mobility in SDS-PAGE of Cas proteins in various cell lines. 
As shown in Fig.  3,  using the  same  amount of whole  ex- 
tract from each cell line, Cas proteins with mobilities simi- 
lar  to  Cas-A  and  Cas-B  from  3Y1  cells were  detected  in 
human breast cancer T-47D  cells, although Cas proteins in 
T-47D  cells showed  slightly faster migration.  Cas  proteins 
of similar mobility to  Cas-A  protein  of T-47D  were  also 
detected  in  human  myelogeneous  cell  lines  HL-60  and 
K562.  On  the  other  hand,  ppl05  that  showed  a  distinct 
mobility  from  Cas-A  and  Cas-B  was  detected  in  human 
myelogeneous cell line U937 and in human T  lymphoblas- 
told cell lines H9,  HPB-ALL,  and Jurkat,  and in human B 
1368  Structure and Function of Cas-L Figure 3.  Differential  expression  of 130- and 105-kD Cas proteins. Ex- 
pression of Cas protein in each cell  line was analyzed  by immunoblotting 
with anti-Cas mAb (lane I, rat 3Y1; lane 2, SR.-3Y1, v-Src transfected 
3Y1  cell strain; lane 3, T-47D; lane 4, HL-60; lane 5; K562; lane 6, 
U937; lane 7, H9; lane 8, HPB-ALL;  lane 9, Jurkat; lane 10, Raji; lane 11, 
whole thymocyte;  lane 12, peripheral B cell; lane 13, peripheral T cell. 
50-1xg lysate per each lane). 
lymphoid cell line Raft. ppl05 was also detected in human 
thymocytes and in  human peripheral T  and B  cells.  The 
expression  level  of  ppl05  varied  widely  among  cells. 
ppl05Cas was significantly overexpressed in H9 cells,  fol- 
lowed by peripheral T  and B  cells,  thymocytes, and Kaji 
cells.  A  110-kD  Cas  protein  that  migrated  more  slowly 
than ppl05 but faster than Cas-A of T-47D cells was also 
detected in  H9  cells,  thymocytes, and  peripheral T  cells. 
These findings indicate that ppl05 is a Cas-related protein 
that is expressed in lymphocytes. 
cDNA Cloning ofpp 105.  To further determine the struc- 
ture  of ppl05,  we  screened the  hgt11  cDNA library de- 
rived from a human T  lymphoblastoid cell line with anti- 
Cas  mAb.  Nucleotide  sequences  of  three  independent 
clones  had  homology with  p130Cas.  These  three  clones 
were cDNAs of an identical transcript, and the nucleotide 
sequences contained an open reading frame of 834 amino 
acids.  The deduced amino acid sequence of this transcript 
showed conserved motifs with p130Cas,  one SH3 domain 
in the NH2-terminal region, and multiple putative binding 
sites of the SH2 domains (Fig. 4 A). Most of the SH2-bind- 
ing  motifs  in  the  substrate  domain  are  YXXP  (YDXP), 
which  are  putative  binding  sites  for  Crk,  Nck,  and  Abl 
SH2 domains  (21).  Despite  the conserved motifs, homol- 
ogy  between  p130Cas  and  the  deduced  amino  acid  se- 
quence of this cDNA is relatively low (Fig. 4 B, 78% in the 
SH3 domain, 32% in the substrate domain, 30% in the spe- 
cific domain, and 52% in the CT). Homology with another 
Cas-related protein, Efs (28), is also relatively low (Fig. 4 B). 
These results indicate that the cDNA encodes a novel Cas- 
related protein. 
To determine whether this cDNA of a novel Cas-related 
protein encodes ppl05, the cDNA was inserted into an ex- 
pression  vector and  transfected into  Cos-1  cells.  Cellular 
lysates from transfectants were analyzed by immunoprecip- 
itation and immunoblotting.  As  shown in  Fig.  5 A,  anti- 
Cas mAb-reactive peptides that migrated at 105 and 110 kD 
in SDS-PAGE were detected (lanes  3 and  7). ppl05 from 
H9 cells (lanes  1 and 5) comigrated with a 105-kD peptide 
detected in  the lysate from the  transfectant and  a  slightly 
slower migrating Cas protein of 110-kD in H9 cells comi- 
grated with a 110-kD peptide. Both Cas proteins detected 
in H9 cells showed faster migration than Cas proteins in 
T-47D (lanes 4 and 8) and Cos-1 cells (lanes 2 and 6). This 
result  strongly suggests  that  (a)  the  Cas-related  gene  en- 
codes ppl05 and (b) a  110-kD Cas protein detected in H9 
cells is the protein product of the same transcript as ppl05, 
despite a different mobility in SDS-PAGE  (similar  to that 
observed with p130Cas-A and Cas-B). 
p130Cas was highly phosphorylated on tyrosine residues 
in  v-Src-  or  v-Crk-expressing  cells  (13).  To  determine 
whether ppl05 is tyrosine phosphorylated by these stimula- 
tions,  an expression vector containing ppl05 was cotrans- 
fected in  Cos-1  cells,  with  expression vectors containing 
activated Src family kinases or Crk. ppl05 was then precip- 
itated by anti-Cas  mAb  and  analyzed by immunoblotting 
with anti-pTyr. As  shown in  Fig.  5  B, ppl05  was  highly 
phosphorylated on tyrosine residues by the  cotransfection 
of Src, Lck, CrkI, or CrklI (lanes 3-6,  respectively). Next, 
to  identify whether  tyrosine-phosphorylated ppl05  binds 
to Crk, lysates of ppl05-transfected Cos cells were immu- 
noprecipitated with anti-Crk mAb and analyzed by immu- 
noblotting with  anti-Cas  mAb.  ppl05  was  coprecipitated 
with Crk only in Cos cells that coexpressed activated Lck 
(Fig.  5  B, lane  8).  Furthermore, ppl05 was  coprecipitated 
with EE-tagged CrkII  (lane  9).  These results  demonstrate 
that tyrosine-phosphorylated ppl05 binds to  Crk proteins 
in vivo. 
Expression of the pp l 05 Transcript.  Using  anti-Cas  mAb, 
we showed cell type-specific expression ofppl05. To fur- 
ther investigate  the  expression of ppl05  in  different cell 
types, expression ofppl05 mRNA was analyzed by North- 
ern blotting. As shown in Fig.  6 A, 5.2- and 3.0-kb RNAs 
were detected in H9  cell polyA  + 1LNA using 32p-labeled 
ppl05 cDNA fragment as a probe. This ppl05 cDNA frag- 
ment expressed the lowest homology with p130Cas.  The 
5.2-kb  R.NA  comigrated with  28S  ribosomal  1LNA  and 
was  detected as a  shifted band in  Northern blotting with 
total RNA.  A smaller amount of ppl05 transcript was  de- 
tected in peripheral T  cells,  and  none was  detected from 
3Y1  and  T-47D  cells.  A  similar  analysis  was  performed 
with  RNAs  from various  tissues.  As  shown  in  Fig.  6  B, 
ppl05  was  expressed in  most tissues  including spleen and 
thymus, although ppl05 was weakly detected in brain and 
liver. This result indicates that ppl05  transcript is ubiqui- 
tously  expressed,  whereas  the  ppl05  protein  is  detected 
only in lymphocytes among the cells investigated. 
Identification of the pp l O  5-binding Proteins.  To  further  de- 
fine the  nature  of ppl05,  we  investigated ppl05-binding 
proteins. As  described previously, ppl05  binds to  FAK in 
vitro. To further characterize ppl05-FAK binding, ppl05 
was  precipitated from H9  cell lysates  with  anti-Cas  mAb 
and analyzed by the overlay assay with a labeled GST-FAK 
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5  S  T  $  5  K  E  S  S  L  S  A  394 
ttc  ctg get  cca  gac ace  gct  art gag  aga ctt  cag  1380 
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Figure  5.  Transfection  study of ppl05.  (A)  Transient  expression  of 
ppl05  in  Cos cells,  pcDL-SRo~ ppl05  was transfected into  Cos-I  cells. 
Cellular lysates of H9,  T-471), and Cos-I  cells were analyzed by imnm- 
noprecipitation  and  imn3unoblotting with  anti-Cas  n3Ab.  (B)  Tyrosine 
phosphorylation  of ppl05  by  cotransfected  Src-family  kinases or  Crk. 
pcDL-SR~ ppl05  was transfected into  Cos-1  cells  with pMT3  (vector, 
lanes 2 and  7), SrcY527F  (lane 3),  LckY505F (lanes 4 and 8),  EE-tagged 
Crkl  (lane 5), and EE-tagged Crk2 (lanes 6 and 9). After lysis, cellular ly- 
sates were inmmuoprecipitated with anti-Cas mAb (lanes  I-6),  anti-Crk 
mAb, anti-EE  tag mAb  (lane  9)  and analyzed by inmmnoblotting with 
anti-Cas mAb and anti-pTyr. 
?0%  32%  30%  S7% 
rat  p130Cas  J ~  I  (YXXP),,I  II  I  .74  a.a. 
(short  form)  P* 
63%  32%  29%  39% 
mouse  Efs  I  ~",.~'~  ~(YXXP)el  II  I  I  58o  a.a. 
p  P* 
Figure  4.  Structure  of ppl05/Cas-L.  (/t)  Nucleotide  and  deduced 
amino  acid  sequences  of ppl05/Cas-L  The  2,765-nucleotide  cDNA 
contains a  single  open  reading flame  that  encodes  a  protein  with  834 
amino acids.  An SH3 domain and putative SH2-binding sites are under- 
lined.  These sequence data are available from GenBank under accession 
number U64317.  (B)  Comparison of amino acid sequences among Cas 
proteins. Amino acid sequence homologies between Cas-L and the other 
Cas protein  in  the  SH3  domain,  substrate domain  (Cas-L residues 92- 
348), specific domain (Cas-L residues 349-628),  and CT (Cas-L residues 
629-834) are shown above each domain. YDYVHL motifs are shown by 
asterisks and vertical lines. Prolme-rich sequences are shown by "P" and 
heavier vertical lines. 
1370  Structure and Function of Cas-L Figure  6.  Expression  ofppl05 transcript. (A) H9 cell polyA  + tLNA was isolated by Fast Track 2.0 (Invitrogen, San Diego, CA), and total cellular 
RNAs were isolated by the method described (26). Northern blot analysis  with a 32p-labeled ppl05 cDNA fragment  was performed  by the method de- 
scribed (26). (B) Tissue distribution of ppl05 was determined by Northern blotting with human tissue blots (Clontech) and the ppl05 probe described 
above. 
fusion  protein.  As  shown  in  Fig.  7  A,  105-  and  l l0-kD 
proteins were detected with labeled GST-FAK fusion pro- 
tein, indicating that both ppl05  and p110-kD Cas protein 
directly bind to FAK. Another FAK-binding protein, pax- 
illin,  was also  detected, as reported previously (20).  To in- 
vestigate the binding of ppl05  to pp125FAK in vivo, co- 
precipitation analysis  using anti-FAK mAb was performed. 
As shown in Fig.  7  B, lanes  7 and  8,  ppl05  was coimmu- 
noprecipitated with pp125FAK from H9 cell lysates,  indi- 
cating in  vivo association between ppl05  and pp125FAK. 
This  pp105-pp125FAK  association  appears  to  be  unaf- 
fected  by  [31  integrin  stimulation  or  subsequent  tyrosine 
phosphorylation  of both  proteins,  because  coprecipitated 
ppl05  showed  no  quantitative  difference  between  FN- 
stimulated and unstimulated cells. 
Next, we attempted to define the proteins that were re- 
cruited  to  ppl05  in  a  phosphorylated  tyrosine  residue- 
dependent manner. For this purpose, lysates from FN-stim- 
ulated H9 cells were precipitated with GST fusion proteins 
that contained SH2 domains from various proteins and an- 
alyzed  by  immunoblotting  with  anti-Cas  mAb  and  anti- 
pTyr.  As  shown in  Fig.  7  C,  110-105-kD  tyrosine-phos- 
phorylated  proteins  were  precipitated  with  GST  fusion 
proteins ofc-Abl, Crk, Csk, Grb2, Lck, Nck, and SHPTP2 
SH2 domains  (anti-pTyr blot),  ppl05  was precipitated by 
GST-AblSH2, GST-CrkSH2, and GST-NckSH2, whereas 
ppl05  was  weakly  precipitated  by  GST-LckSH2,  GST- 
SHPTP2SH2, and GST-CskSH2 (anti-Cas blot). To deter- 
mine  whether  the  binding  of ppl05  to  these  GST fusion 
proteins was induced by [31  integrin stinmlation,  a similar 
analysis  was  performed  by  using  lysates  of H9  cells  that 
were incubated in PLL- or FN-coated plates. As shown in 
Fig.  7  D,  enhancement  of ppl05  precipitation  was  ob- 
served in the lanes of GST-SH2 domain fusion proteins of 
c-Abl, Crk, and Nck, whereas increased but slight amounts 
of ppl05 were detected in the lanes of the GST-SH2 do- 
main fusion proteins of Lck and SHPTP2. These results in- 
dicated  that  tyrosine-phosphorylated ppl05  binds  to  SH2 
domains of c-Abl, Crk, Lck, Nck, and SHPTP2 in vitro. 
To further determine if these ppl05-binding proteins bind 
to ppl05 in vivo, coimmunoprecipitation analysis ofppl05 
with these proteins was performed. As shown in Fig.  7 E, 
ppl05  was  coprecipitated  with  Crk  and  Nck,  whereas 
ppl05  was  weakly  coprecipitated  with  SHPTP2.  Unlike 
pp125FAK-pp105  binding,  ppl05  that was coprecipitated 
with Crk,  Nck,  or SHPTP2 was increased by [31  integrin 
stimulation with FN. These results indicate that [31 integrin 
stimulation leads to the recruitment of various proteins, in- 
cluding Crk, Nck, and SHPTP2, to the tyrosine-phosphor- 
ylated ppl05,  in addition to stimulation-independent  asso- 
ciation  with  pp125FAK.  These protein-protein  interactions 
further suggest the putative function ofppl05 in the 131 in- 
tegrin-mediated signaling pathways. 
Discussion 
We reported previously that the engagement of [31 inte- 
grins  induced  tyrosine phosphorylation of a  105-kD  pro- 
tein  (ppl05)  in  H9  cells  and  peripheral  T  cells  (10-12). 
ppl05 was one of the major proteins in T  cells that was ty- 
rosine  phosphorylated by [31  integrin  stimulation.  In  this 
study,  we  identified  ppl05  as  a  tyrosine-phosphorylated 
1371  Minegishi  et al. Figure 7.  Identification of the ppl05-binding proteins.  (A) H9 cell lysates were immunoprecipitated  without first Ab (lane I), with anti-Cas mAb (lane 
2), and with antipaxillin mAb (lane 3), respectively. After fractionation by SDS-PAGE and electrotransfer, immunoprecipitates  were denatured  and rena- 
tured and were overlayed with 32p-labeled GST-FAK fusion protein containing FAK residues 707-1,052.  (B) H9 cells were incubated in PLL- or FN- 
coated plates (lanes 1, 3, 5, and  7 and lanes 2, 4, 6, and 8, respectively) for 30 rain. Cells were lysed in 1% digitonin  lysis buffer, and cellular lysates were 
imnmnoprecipitated  without first Ab (lanes 3 and 4) or with anti-Cas mAb (lanes 5 and 6) or anti-FAK mAb (lanes 7 and 8). Whole lysates (lanes I and 
2) and immunoprecipitates  were analyzed by immunoblotting with anti-Cas mAb. (C) Cellular lysates of FN stimulated H9 cells were precipitated with 
GST- (lane 3),  GST-AblSH2- (lane 4),  GST-CrkSH2- (lane 5),  GST-CskSH2- (lane 6), GST-Grb2SH2- (lane  7),  GST-LckSH2- (lane  8),  GST- 
NckSH2- (lane 9), GST-PI3Ka- (lane 10),  GST-PLC~/SH2- (lane 1l), GST-ShcSH2- (lane 12),  and GST-SHPTP2SH2- (lane 13)  conjugated  beads. 
Whole lysates (lanes 1 and 2) and the precipitates were analyzed by immunoblotting with anti-Cas lnAb (left) and rehybridized with anti-pTyr (ri~,ht). (D) 
H9 cells were incubated  in PLL- or FN-coated plates (lanes 2,  4,  6,  8,  10,  12,  14,  I6,  and  18 and lanes  I,  3,  5,  7,  9,  1I,  13,  15,  17, and  19, respec- 
tively). After lysis, cellular lysates were precipitated  with GST- (lane 1), GST-AblSH2- (lanes 2 and 3), GST-CrkSH2- (lanes 4 and 5), GST-CskSH2 
(lanes 6 and  7), GST-Grb2SH2- (lanes 8 and  9),  GST-LckSH2- (lanes I0 and  1  I), GST-NckSH2- (lanes 12 and  13),  GST-PI3KSH2- (hues  14 and 
1~, GST-ShcSH2- (lanes 16 and  17), and GST-SHPTP2SH2- (lanes 18 and  19) conjugated beads. Precipitates were analyzed by imnmnoblotting with 
anti-Cas mAb and rehybridized with anti-pTyr.  (E) H9 cells were incubated  in PLL- or FN-coated plates (lanes 1, 3, 5,  7, 9, and  11 and lanes 2, 4,  6, 
8,  I0, and  12, resi~ectively) for 3(I rain and lysed in 1% digitonin lysis buffer.  Cellular lysates were immunoprecipitated  without first Ab (lanes 3 and 4) 
or with anti-Nck mAb (lanes 5 and 6), anti-Crk mAb (lanes 7 and 8), anti-SHPTP2 mAb (lanes 9 and  10), or anti-Cas mAb (lanes 11 and  12).  Whole ly- 
sates (lanes 1 and 2) and immunoprecipitates  were analyzed by immunoblotting with anti-Cas nrAb. 
p130Cas-related  protein,  determined  its  structure  and  dis- 
tribution,  and  further  demonstrated  the  putative  function 
of ppl05  through  its recruitment  of SH2  domain-contain- 
ing proteins. 
ppl05  and  p130Cas  share  several  similar  characteristics. 
Both  of them  are  tyrosine  phosphorylated  by  the  engage- 
ment of [31  integrins and both are pp125FAK-binding pro- 
teins (11,  12,  18,  19).  Both ppl05  and p130Cas  are tyrosine 
phosphorylated  by  the  cotransfection  of activated  Src  or 
Crk,  and  both  bind  to  Crk  in  a  tyrosine  phosphorylation- 
dependent  manner  (13).  Structurallyl  the  deduced  amino 
acid sequence of each Cas protein contains one highly con- 
served SH3 domain and multiple binding sites for SH2 do- 
mains.  The  SH3  domain  of Cas  is  the  FAK  binding  site 
(19;  Tachibana,  K.,  unpublished  data),  ppl05  contains  13 
repeated  YXXP  motifs  (7  YDXP  motifs)  in  the  substrate 
1372  Structure and Function of Cas-L domain,  whereas  pl30Cas  contains  15  repeated  YXXP 
motifs  (9 YDXP motifs)  (13).  The other Cas  family pro- 
tein, p83Efs, contains 8  repeated YXXP motis  (4 YDXP 
motifs)  (28).  These motifs are reported to be the putative 
binding  sites  of the  SH2  domains  of Crk,  Nck,  and  Abl 
(21).  In addition,  each Cas protein contains one conserved 
YDYVHL motif in the CT. This motif is weakly homolo- 
gous to the predicted binding sites of the Src SH2 domain 
and of the SHPTP2 SH2 domain, although the protein(s) 
that binds to this motif has not yet been determined. The 
CT is relatively conserved among these three Cas proteins, 
suggesting  that  this  domain  has  an  important  function(s) 
common to Gas proteins. 
Besides these conserved motifs, there is one motif that is 
not conserved in ppl05, p130Cas and p83ER contain proline- 
rich sequences (RPLPXPP) upstream from the YDYVHL 
motif,  although ppl05  does  not  contain  these  sequences. 
These  sequences  have been reported to  be putative  SH3 
domain-binding sites, and p83Efs was originally cloned as a 
Fyn SH3 domain-binding protein (28).  This difference in 
structure may result in the difference between protein in- 
teractions and in the difference in function between ppl05 
and the other Cas family proteins. 
The largest difference between ppl05  and p130Cas was 
the cell type distribution.  We previously identifed ppl05 
in  human  T  lymphocytes  (11),  whereas  Sakai  et  al.  (13) 
identified p130Cas in fibroblasts.  In this study, we demon- 
strated the expression of Cas  proteins in various cell lines. 
p130Cas  was  predominantly expressed in  a  human  breast 
cancer cell line,  T-47D,  as  well  as  in  rat  fibroblast 3Y1. 
ppl05 was predominantly expressed in human lymphocytes. 
However,  Northern  blotting  with  tissue  RNAs  showed 
ubiquitous  distribution  of ppl05,  suggesting  that  the  ex- 
pression of ppl05  is not limited to lymphocytes, p130Cas 
transcript was reported to be ubiquitously expressed, espe- 
cially in  the brain,  lung,  intestine,  kidney, and  testis  (13). 
On  the  other  hand,  another  Cas  family protein,  p83Efs, 
was  reported  to  be  expressed  in  the  embryo,  placenta, 
brain, and skeletal muscle but not in the spleen (28).  These 
results  indicate that ppl05 is the dominant Cas protein in 
lymphocytes, whereas p130Cas  is  the  dominant  Cas  pro- 
tein in fibroblasts.  In addition to this reciprocal expression, 
ppl05 RNA is not well expressed in brain and liver. This 
interesting observation may suggest  the putative  function 
and/or promoter specificity ofppl05. 
Based  on  the  notion  that  ppl05  is  a  p130Cas-related 
protein,  we  attempted  to  define the  putative  function  of 
ppl05. Because ppl05 is tyrosine phosphorylated by [31 in- 
tegrin stimulation in H9 cells and in peripheral T  lympho- 
cytes,  it  is  conceivable that  phosphorylated tyrosine resi- 
dues  of ppl05  are  involved  in  the  transduction  of ]31 
integrin-mediated  signals.  If so,  how  is  ppl05  tyrosine 
phosphorylated by the stimulation of ]31 integrins? We re- 
ported previously that ppl05  was tyrosine phosphorylated 
with similar kinetics to pp125FAK phosphorylation by FN 
stimulation  in  H9  cells  (12).  The  presence  of pp105- 
pp125FAK binding suggests the involvement of FAK in the 
[31  integrin-mediated  tyrosine  phosphorylation  of ppl05, 
because FAK itself is activated and autophosphorylated by 
[31 integrin stimulation (29).  It has also been reported that 
autophosphorylated FAK bound  to  Src  SH2  domain  and 
formed a stable  complex (30),  and cotransfected Src family 
tyrosine kinases  have been shown to phosphorylate ppl05. 
Taken together, these observations suggest that pp125FAK 
itself,  and/or  FAK-associated  Src-family  kinases,  are  in- 
volved  in  integrin-mediated  tyrosine  phosphorylation  of 
ppl05. 
The second question to be considered is how tyrosine- 
phosphorylated ppl05 transduces downstream signals. Because 
one of the major functions of protein tyrosine phosphory- 
lation is phosphorylated tyrosine-mediated protein-protein 
interaction, we investigated proteins that were recruited to 
ppl05  by [31  integrin  stimulation.  We  demonstrated  that 
Crk  and  Nck  were  recruited  to  Wrosine-phosphorylated 
ppl05  both  in  vivo  and  in  vitro.  SHPTP2  was  also  re- 
cruited, although this association was weak. These proteins, 
which are recruited to ppl05, appear to be involved in [31 
integrin signaling via their recruitment to ppl05. 
ppl05  contains  multiple  putative  binding  sites  for the 
Crk SH2 domain, and tyrosine-phosphorylated ppl05 binds 
to  Crk.  Crk  is an  adapter protein  composed of SH2 and 
SH3 domains. Crk binds to SOS and another guanine nu- 
cleotide exchange protein, C3G, through its SH3 domain. 
Recently, our and several other laboratories reported that 
[31  integrin stimulation induces activation of Erk  (10,  31, 
32). Crk was reported to be involved in Ras activation by 
the  recruitment  of  SOS  (14).  Tyrosine-phosphorylated 
ppl05 may be involved in the recruitment of SOS via Crk, 
and  recruited SOS activates Ras  and Erk  (33).  However, 
Crk has been reported to bind to C3G better than to SOS, 
and membrane-anchored C3G activated another small GTP- 
ase, RaplA/K-revl, which inhibited Ras-mediated signals 
by competition (34). These reports suggest that recruitment 
of Crk to tyrosine-phosphorylated ppl05 may be involved 
in the regulation of Erk signals through Ras and Rap1A. 
Nck is another adapter protein that contains three SH3 
domains  and  one SH2  domain  (35).  It has  been reported 
that overexpression of Nck resulted in oncogenic transfor- 
mation in fibroblasts (35),  although the native function of 
Nck has not yet been identified. However, ppl05 contains 
multiple putative binding sites  for the  Nck  SH2  domain, 
and  tyrosine-phosphorylated ppl05  recruited Nck.  These 
findings strongly suggest the involvement of Nck in [31 in- 
tegrin-mediated signaling. 
SHPTP2 is a cytoplasmic tyrosine phosphatase with two 
SH2 domains (36).  Recently, it was  reported that a domi- 
nant-negative  SHPTP2  mutant  inhibited  the  insulin- 
dependent dephosphorylation of FAK (37).  SHPTP2 is re- 
cruited to tyrosine-phosphorylated ppl05 through its own 
SH2  domain,  and  the  deduced  amino  acid  sequence  of 
ppl05  contains  a  possible  binding  site  for  the  SHPTP2 
SH2 domain. This recruitment of SHPTP2 to ppl05 could 
be involved in the dephosphorylation of FAK and ppl05. 
ppl05, as well as p130Cas, is tyrosine phosphorylated by 
1373  Minegishi  et al. the overexpression of Crk proteins. Since Crk itself does not 
contain a catalytic domain characteristic of protein tyrosine 
kinases, overexpressed Crk may recruit a tyrosine kinase(s) 
to ppl05,  c-Abl is known to bind to the Crk SH3 domain 
(38) and was reported to phosphorylate tyrosine residues of 
p130Cas in vitro (39). In addition, tyrosine-phosphorylated 
ppl05 bound to the c-Abl SH2 domain in vitro. Unfortu- 
nately, we have been unable to demonstrate in vivo bind- 
ing of ppl05 to c-Abl. However, findings described above 
suggest  that  c-Abl may interact and  phosphor/late  ppl05 
directly or via the binding to Crk. 
In summary, ppl05, one of the major tyrosine phosphor- 
ylated proteins induced through the ligation of [31  integrin 
on  the  surface  of lymphocytes,  is  identified  as  a  novel 
p130Cas-related protein, ppl05 is the major Cas protein in 
lymphoid cells, whereas p130Cas is the major Cas protein 
in  fibroblasts,  ppl05  is  directly associated with  the  FAK 
COOH-terminal  region  in  an  integrin  stimulation-inde- 
pendent manner,  and tyrosine phosphorylated ppl05 binds 
to the SH2 domains of Crk, Nck, and SHPTP2  in T  cells. 
These findings reveal a  novel architecture  of [M  integrin- 
mediated protein tyrosine phosphorylation and further sug- 
gest  the  involvement  of Crk,  Nck,  and  SHPTP2  in  the 
downstream pathways of131  integrin-mediated signaling. 
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